Wheeling and dealing his way to a cancer drug pipeline, Gilead’s Dan O’Day crafts a rich, $805M deal to bag a preclinical I/O drug

Looking to leap into the front of an incipient race to develop anti-CCR8 drugs for cancer, Gilead has plunked down $120 million in cash and …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wheel­ing and deal­ing his way to a can­cer drug pipeline, Gilead’s Dan O’Day crafts a rich, $805M deal to bag a pre­clin­i­cal I/O drug